Background/Aims: Cholestasis is the major cause of the accumulation of bile acids and results in liver damage, fibrosis, and failure. A growing number of studies have shown that gentiopicroside is a promising prospect that may protect the liver. However, its therapeutic mechanism has not yet been clarified. This study aimed to explore the effect and mechanism of gentiopicroside in cholestasis induced by alpha-naphthylisothiocyanate. Methods: We performed isobaric tags for relative and absolute quantification-based quantitative proteomics and metabolomics using liquid chromatography quadruple time-of-flight mass spectrometry and identified the expression of 73 metabolites and 84 proteins associated with cholestasisrelated dysfunctions in the metabolism of bile acids, fatty acids, and glycerophospholipids. Results: Integrated analyses of proteomic and metabonomic studies showed altered pathways in cholestasis-induced liver injury involving increased activity of farnesoid X receptor/retinoid X receptor, bile acid biosynthesis, and peroxisome proliferator-activated receptor-α/retinoid X receptor-α. Gentiopicroside could reverse these metabolite, protein, and blood biochemical indices, as well as alleviate liver damage. The progressive changes in the proteins and genes may be correlated with cholestasis and were confirmed by western blot and quantitative realtime polymerase chain reaction. Conclusion: Gentiopicroside could be used to protect the liver in the presence of cholestasis.
Introduction
Bile formation is a vital function of the liver in all vertebrates. Bile acids (BAs) are the major constituents of bile. They stimulate bile secretion and are required for intestinal absorption of lipids and fat-soluble vitamins. BAs also modulate gene expression through signal transduction pathways that regulate lipid metabolism and energy expenditure [1] . However, disruption of BA excretion results in BA accumulation in the liver, which can result in hepatotoxicity and even lead to cirrhosis and hepatic necrosis [2, 3] . Despite this wellknown sequence of events, the molecular mechanisms by which BAs injure the liver remain unclear. Additionally, there are few treatments available for cholestasis. One hypothesis is that toxic BAs induce hepatocyte apoptosis by activating death receptors [4] . This hypothesis was based primarily on in vitro observations from cultured cells exposed to high concentrations of toxic BAs [5, 6] . However, such high concentrations are rarely observed in sera from cholestatic patients and animal models [7, 8] . Most importantly, hepatocyte apoptosis has not been detected in vivo in the livers of bile duct ligated mice or in vitro in BA-treated human hepatocytes [9, 10] , which suggests that BA-induced liver injury occurs by alternative mechanisms.
Ursodeoxycholic acid (UDCA) is the only drug currently available to treat cholestasis that has been approved by the US Food and Drug Administration. However, the efficacy of UDCA is inconsistent, and it has no effect on some patients with cholestasis [11] . Therefore, new therapies are urgently needed because of the limitations of this drug [12] . Gentiopicroside (GPS), which is an active compound isolated from the plant Gentiana rigescens Franch.ex Hemsl, has been used for the treatment of jaundice and other hepatobiliary diseases in China [13] . Several studies have shown that GPS has protective effects on the hepatobiliary system [13] [14] [15] . In recent years, the mechanisms of chemicals and Chinese herbal medicines in liver diseases [16] [17] [18] [19] [20] such as liver fibrosis [21] [22] [23] have been investigated. In addition, metabolomics has also been used to study the mechanisms of disease by detecting small metabolites produced by normal or pathological cellular processes [24] . Several serum metabolites have been identified as novel biomarkers of cholestasis induced by alphanaphthylisothiocyanate (ANIT) [25] . However, proteomics and metabolomics have not been simultaneously used to study ANIT-induced cholestasis. ANIT is a model hepatotoxin for cholestatic hepatitis, which can cause cessation of bile flow in vivo, hepatic parenchymal cell damage, and infiltration of neutrophils around bile ducts [11] .
In the present study, based on ANIT-induced cholestasis, we explored the anti-cholestatic effect of GPS via a proteomics profile of the liver and untargeted metabolic profiling of the liver, serum and urine based on liquid chromatography (LC)-mass spectroscopy (MS). The results showed that a series of differentially expressed proteins (DEPs) and metabolites were altered during the development of liver injury. These molecules are primarily involved in the metabolism of BAs, fatty acids (FAs), and lipids. Thus, we suggested a potential novel sequential mechanism to explain the initiation of BA-induced liver injury in cholestasis and highlight the potential therapeutic effects of GPS for cholestatic hepatitis. were ultrasonicated at 4 °C for 3 min (80 W, on for 0.8 s and off for 0.8 s) and centrifuged at 12, 000 rpm at 4 °C for 10 min. Supernatants were collected, and cooled acetone was added. The solution was centrifuged at 12, 000 rpm for 10 min at 4 °C. The precipitates were collected, and cooled acetone was added. The solutions were centrifuged at 12, 000 rpm for 15 min at 4 °C, and the isolates collected. This step was performed twice. The isolates were dissolved in lysis solution. The solution was centrifuged at 12, 000 rpm for 15 min at 25 °C. Supernatants were again collected and centrifuged. The concentrations of the proteins in the supernatants were detected by the bicinchoninic acid method.
Preparation of protein samples
Proteins (100 μg) were obtained from each pooled sample, and cold acetone with four-fold volumes of the proteins was added at −20 °C and incubated for 1 h. The solutions were centrifuged at 12, 000 rpm for 15 min at 4 °C. The precipitates were collected and freeze-dried. After 50 μL of the dissolution buffer and 4 μL of the reducing reagent were added, the samples were incubated at 60 °C for 1 h. Then, 2 μL of cysteineblocking reagents were added at 25 °C for 10 min. The solutions were centrifuged at 12, 000 rpm for 20 min to clean the protein solution. After adding 100 μL of dissolution buffer, the solutions were centrifuged at 12, 000 rpm for 1 min. This step was repeated three times. The solutions were transferred to new tubes, and 50 μL of sequencing-grade trypsin (50 ng/μL) was added and tubes were incubated at 37 °C for 12 h. Solutions were centrifuged at 12, 000 rpm for 20 min, and the peptides were collected. The filter units were transferred to new tubes, and dissolution buffers (50 μL) were again added to the tubes.
Protein labeling and MS analysis
The 8-plex iTRAQ Reagent Multiplex Kit protocol (Applied Biosystems, Foster City, CA) was used for differential labeling. The control, ANIT, M-GPS, and UCDA groups were labeled as follows: 113, 114; 115, 116; 117, 118; and 119, 121. Pooled samples were mixed and dried. The dried sample was resuspended with 100 μL of buffer A (20 mM ammonium formate, water, pH 10). Fractionation was performed using the Ultramex SCX column (4.6 mm × 250 mm) with UV detection at 215 nm and 280 nm. Separation was performed as follows: 0-5 min, 5% B (20% 20 mM ammonium formate, 80% ACN, pH 10); 5-30 min, 5-15% B; 30-45 min, 15-38% B; 45-46 min, 38-90%; 46-54.5 min, 90% B; 54.5-55 min, 90-5% B; and 55-65 min, 5% B. The flow rate was 0.8 mL/min. Each segment was collected at intervals of 1 min for the 8-65 min, and five tubes were mixed to give a total of 10 segments. All segments were dried in a vacuum freeze dryer for further LC-MS/MS analysis.
Reversed-phase LC-MS/MS analysis
Dried samples were resuspended with 60 μL of 2% ACN and 0.1% formic acid. Separation was performed on the Eksigent NanoLC-Ultra TM system with NanoLC trap ChromXP C18 (350 μm × 0.5 mm, 3 μm, 120 A) and washed with buffer A (0.1% formic acid, water) and buffer B (98% ACN, 2% water, 0.1% formic acid) at 3 μL/min. The 90-min gradient was 0-0.1 min, 5-10% B; 0.1-60 min, 10-28% B; 60-75 min, 28-50% B; 75-75.5 min, 50-80% B; 75.5-80 min, 80% B; 80-80.5 min, 80-5% B; 80.5-90 min, 5% B. Data were acquired by AB SCIEX TripleTOF TM 5600 with an ion spray voltage of 2.5 kV, curtain gas of 30 psi, nebulizer gas of 5 psi, and an interface heater temperature of 150 °C. A full-scan MS experiment (scan range 800-4000 m/z) was performed, followed by MS/MS on the top 30 ions detected. The MS/MS scan range was 100-1800 m/z at a resolution of 20, 000 and the scan time was 100 ms.
Protein identification, quantification, and pathway analysis
Protein Pilot Software v. 5.0 (AB Sciex, Foster City, CA) was used for peak analysis and data processing with the Uniprot rat database (http://www.uniprot.org/). The fold changes among proteins in different groups were calculated as average values from the protein isobaric tags for relative and absolute quantification ratios. The P value was calculated using the Student's t-test via SPSS 19.0. P < 0.05 and a fold change of more than 1.3 or less than 0.77 were considered statistically significant. Differentially expressed DEP classification was based on functional annotations using Gene Ontology (GO) analysis for molecular functions, biological processes, and cellular components.
Pathway analysis and interactive network construction by Ingenuity Pathway Analysis software
For pathway and network analyses, the differentially expressed metabolites and DEPs (with KEGG IDs, UniProt IDs) and their fold change directions were encoded into the Ingenuity Pathways Analysis (IPA) software (Ingenuity Systems, Mountain View, CA). This software is web-based and suggests possible biochemical, molecular, and biological functions of the input metabolites and proteins. The molecular interaction networks among the proteins and metabolites were constructed based on the database of IPA. 
Quantitative real-time PCR analysis
Total RNA in liver samples was extracted by an RNA extraction kit according to the manufacturer's protocol (Takara Bio, Inc., Kusatsu, Japan). Reverse transcription and quantitative real-time PCR (qRT-PCR) were performed to evaluate the expression of ALDH1L1, ABCB4, ABCB11, MRP4, CYP2A12, CYP7A1, and farnesoid X receptor (FXR). Total RNA (1 µg) was reverse-transcribed to the first-strand cDNA by Prime Script TMRT Master Mix (Takara Bio, Inc.), and then the expression levels of mRNA were quantified by real-time PCR using SYBR premix Ex TaqTM (Takara Bio, Inc.). The PCR program included 1 cycle at 95 °C for 30 s, 40 cycles at 95 °C for 5 s, and 60 °C for 30 s. The results were expressed by calculating the 2-ΔΔCT values. Data were normalized with GAPDH for variance. The PCR primer pairs of all genes are shown in Table 1 .
Western blot
Antibodies against STAT3 and NQO1 (Sigma-Aldrich) were used for western blot analysis. The liver samples were lysed using RIPA (Beyotime, Shanghai, China), and the protein concentration was determined by a Bradford kit (Beyotime). Protein (30 μg) was loaded and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis gels, and then the gels were electrophoretically transferred onto a polyvinylidene fluoride membrane (Beyotime). After blocking with 5% nonfat dry milk in Tris-buffered saline, the membranes were incubated with antibodies diluted according to the manufacturers' instructions. Secondary antibodies were incubated with antibodies for STAT3 and NQO1 for 1 h at 25 °C, and the images were captured by the Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE). Proteins were quantified using Quantity One imaging software (Bio-Rad Laboratories, Hercules, CA) and normalized with GAPDH.
Results

Histological changes in ANIT-induced cholestasis rats and GPS-treated groups
ANIT can induce toxicity and cholestasis ( Fig. 1 ). In the GPS-treated group, the area of liver injury decreased significantly and tended towards becoming normal liver tissue; the moderate-dose treatment group showed the most obvious effects (Fig. 1) . In our study, serum ALT, ALP, TBA, and TBIL levels increased in the ANIT group, and these were reversed in the GPS group, suggesting severe liver injury and cholestasis. Although UDCA only reversed ALP and TBA, the GPS group reversed all increases in the levels of ALT, ALP, TBA and TBIL, especially in the M-GPS-ANIT group (Table 2) . These results suggested that GPS protected against ANIT-induced hepatocyte injury and intrahepatic cholestasis.
Metabolite profiles and markers of ANIT-induced cholestasis
Representative total ion current chromatograms of serum in the six groups obtained from the positive and negative ion modes are shown in Fig. 2 . A PCA model of the serum, liver, and urine metabonomics of each group, and the profiles of the different groups showed a tendency towards separation (Fig. 3) . The PLS-DA scores plot (Fig. 4) showed three clusters in the six groups. The ANIT group was clearly separate from the healthy controls. A total of 126 serum metabolites were found to be the most significantly altered in the ANIT group relative to the control. L-GPS-ANIT, M-GPS-ANIT, H-GPS-ANIT, and UDCA groups reversed 92, 106, 96, and 39 of these altered metabolites, respectively. In the liver tissue, 109 serum metabolites were altered in the ANIT group compared with the control group. The L-GPS-ANIT, M-GPS-ANIT, H-GPS-ANIT, and UDCA groups reversed 42, 59, 65, and 30 of these metabolites, respectively. Among the urine metabolites, 99 were identified in the ANIT group compared with the control group. L-GPS-ANIT, M-GPS-ANIT, H-GPS-ANIT, and UDCA groups reversed 70, 66, 66, and 54 of these metabolites, respectively. These results indicated that GPS can improve ANIT-induced liver injury to a greater degree than the positive drug UDCA. This finding was consistent with the serum biochemical parameters and liver histopathological findings. Five markers in the serum, urine, and liver showed the same changes. A total of 14 markers showed the same changes in sera and urine. Four markers showed the same trend in the sera and liver tissue, and 11 showed the same trend in the urine and liver tissues (Fig.  5 , Table 3 ).
Metabolite markers of cholestasis
Five differentially expressed metabolites in sera, urine, and liver that are associated with cholestasis (Fig. 5, Table 3 ) were upregulated in the ANIT group compared with the controls. These metabolites, which included taurallocholic acid, cholic acid, phosphatidylglycerol (PG; 17:0/0:0), tauroursodeoxycholic acid, and phosphatidic acid (PA; 10:0/10:0), could be considered specific potential markers for liver cirrhosis and hepatitis. These metabolites were reversed in the L-GPS-ANIT, M-GPS-ANIT, and H-GPS-ANIT groups in the serum, liver, and urine samples, whereas UDCA could only reverse taurallocholic acid and cholic acid.
DEPs
A total of 84 proteins, including 31 upregulated-and 53 downregulated-proteins, were differentially expressed in the ANIT group compared with the control group. Additionally, 26 DEPs were reversed in the M-GPS group, while UDCA only reversed 8 proteins (Table  4) . Analysis of the cell components revealed that most of the 84 DEPs were annotated cytoplasmic part proteins. From the results obtained from GO analysis, the most significantly enriched pathway was associated with catalytic activity. Analysis of the biological processes showed that these proteins were mainly involved in small molecule metabolism, oxidationreduction, and single-organism metabolism. The upregulated proteins were bile salt export pumps, CP270, cytochrome P450, CYP2C70, STAT3, signal transducer and activator of transcription 4, ABCB4, ATP-binding cassette sub-family D member 3, NQO1, and NAD(P) 
Verification of proteomics by western blotting
The results of proteomics analysis showed upregulated expression levels of STAT3 and NQO1 in the ANIT group (Fig. 6 ). This result was verified by western blot to detect the expression levels of proteins in the total liver proteins from the ANIT, M-GPS, and control groups. The expression levels of STAT3 and NQO1 in GPS (120 mg/kg) group were downregulated compared with proteins of the ANIT group and upregulated compared with those of the control group. This finding was consistent with the results from proteomics analyses.
Pathway analysis and interactive network of the metabolites and proteins
The differentially expressed metabolites and proteins (Table 4) were imported into IPA software to review the biological functions, canonical pathways, and significant network analyses. The analyses of diseases and disorders, molecular and cellular functions, and physiological system development and functions were carried out. We systematically evaluated the functions of the identified metabolites and proteins by investigating the results of interactive network analysis (see Supplementary Figure S1 -for all supplementary material see www.karger.com/10.1159/000493409). 
Gene expression in ANITinduced cholestasis rats and the GPS group
The mRNA levels of the transporters and metabolic enzymes were quantified by qRT-PCR (Fig. 7) . The results showed that the gene expression levels of FXR, ABCB11, ABCB4, and Mrp4 in the ANIT-treated group significantly decreased (##p<0.01, #p<0.05 vs. control; **p<0.01, *p<0.05 vs. ANIT). GPS pretreatment significantly upregulated the expression of FXR, Cyp7a1, Mrp4, and ABCB11 mRNA levels than the ANIT group.
Discussion
Cholestasis is one of the most common and devastating liver diseases. This disease is characterized by dysfunction of hepatocytes or obstruction of bile ducts, resulting in the accumulation of toxic BAs in the liver [26] . In cholestasis, serum and liver BA levels are elevated and result in hepatic injury. To date, the pathogenesis of BA-induced liver injury remains ambiguous, and the treatment options are limited [27] . Currently, UDCA is the only widely used drug for treating cholestatic diseases. However, the efficacy of UDCA is inconsistent and it is ineffective in some patients [11] . According to previous studies, GPS has an anti-cholestatic effect and could be considered as an alternative to UDCA, although the mechanism is still unclear. In this report, conventional methods were used to study the effects of GPS on cholestasis. We identified differences among the proteins and metabolites between normal, ANIT-induced cholestatic samples, and GPS-treated samples using proteomics and metabolomics to evaluate the mechanism of BA-induced liver damage and determine the possible protective mechanism of GPS in ANIT-induced liver injury. We built the proteins and metabolite interaction network of GPS against cholestasis. The results showed that GPS had protective effects on cholestasis by reversing potential biomarkers to normal levels. Moreover, 36 metabolites were regulated in the primary BA biosynthesis pathway, in glycerophospholipid metabolism, and in FAs metabolism. GPS, especially at the moderate dose, could reverse most of these effects. Taurallocholic acid, cholic acid, PG (17:0/0:0), tauroursodeoxycholic acid, and PA (10:0/10:0) were upregulated in sera, the liver, and urine. This result suggested that these metabolites might be biomarkers of cholestasis.
Glycerophospholipid metabolism focuses on phosphocholines (PCs), PGs, and PAs, which are the main lipid components of biomembranes. PC molecules are involved in many biological processes such as cell signaling, energy metabolism and storage, and cell membrane integrity. In our study, PCs were increased in the ANIT group, and the activation of lipid metabolism indicated an attempt to repair and reduce cell membrane and cell damage [28] . Recent studies have also shown that increasing levels of phosphatidylcholine can reduce the levels of cholesterol and reduce liver damage effects in the body [29] . In addition, taurocholic acid, glycocholic acid, taurochenodeoxycholic acid, and glycochenodeoxycholic acid were upregulated significantly in the ANIT group versus the control group, but GPS downregulated the levels of these metabolites remarkably in the serum, urine, and liver. The levels of these BAs are elevated in patients with cholestasis [10] . The accumulation of several hydrophobic BAs during cholestasis leads to apoptosis and inflammation in hepatocytes [30] . Network analysis revealed that BA biosynthesis was activated, and CYP3A4, CYP3A, and CYP7A1 were found to be involved in the biosynthesis of BAs (Supplementary Figure S1) . qRT-PCR results confirmed that CYP7A1 was upregulated in the ANIT group, and GPS treatment could reverse 
Signal transducer and activator of transcription 3 this effect. CYP7A1 was the rate-limiting enzyme in the synthesis of BAs. GPS inhibited the expression of CYP7A1 to reduce the biosynthesis of BAs, thus the process could protect the liver from injury induced by BAs. These results may partially indicate a possible therapeutic mechanism through BA synthesis and secretion. Proteomics analyses of the liver identified 53 downregulated and 31 upregulated proteins in the ANIT group versus the control group. The DEPs were primarily involved in the oxidation of FAs and lipid metabolism. FAs beta-oxidation plays a key role in liver steatosis, fibrosis, and eventually cirrhosis [31, 32] . Canonical pathway analyses of differentially expressed metabolites and DEPs were performed in the ANIT group and compared with the control group. The top five pathways associated with cholestasis, LXR/retinoid X receptor (RXR), and FXR/RXR activation were found to be significantly different. Previous studies indicated that LXR is involved in cholesterol and lipid metabolism and orchestrates the inflammatory response by inhibiting the expression of inflammatory mediators stimulated by LPS, tumor necrosis factor-α, and interleukin-1β [33] [34] [35] . FXR, which is an endogenous and physiologically relevant ligand, and one of the most important upstream nuclear receptors. Recent studies have suggested that FXR has a complementary role in the regulation of genes in the synthesis and transport of BAs [36, 37] . Cholestasis-related transporters and enzymes have adaptive responses through the activation of FXR, indicating that FXR may become the focus of targeted therapies in cholestasis as the key regulatory transcription factor for BA [38] . FXR can suppress the expression of Cyp7a1, the rate-limiting enzyme in BA synthesis [39] . The loss of FXR can rapidly result in cholestasis and liver injury [40] . A moderate dose of GPS (120 mg/kg) could significantly upregulate the expression of FXR, which may suppress the expression of CYP7A1. These results were confirmed by qRT-PCR (Fig. 7) . In addition, GPS was shown to significantly upregulate the expression of Mrp4 mRNA in rat livers at a dose of 120 mg/kg. Mrp4 can transport BAs from the hepatocytes into the bile [41] . The elevation of Mrp4 could facilitate hepatic BAs into the canaliculus and thus reduce the risk of liver injury. In addition, Mrp4 mediates the export of bilirubin conjugates from hepatocytes [42] . Studies have reported that ATP-binding cassette (ABC) transporters are responsible for transporting BAs across the canalicular membrane against their concentration gradients. The bile salt export pumps (ABCB11 and ABCB4) are mainly responsible for BA transport from the hepatocytes into the bile canaliculi. In the current study, GPS treatment significantly suppressed the expression of ABC11 and ABCB4 (Fig. 7) . This result indicated that GPS could prevent BAs from refluxing into the liver against their concentration gradients and reduce ANIT-induced liver injury. As a summary, we produced a brief GPS action diagram (Fig. 8) . GPS can up-regulate the expression of FXR, inhibit the synthesis of CYP7A1, reduce the synthesis of BAs, and accelerate the secretion of bile into the bile ducts from the liver by upregulating the expression of ABCB4 and ABCB11.
Conclusion
In this study, we analyzed ANIT-induced cholestasis using i-TRAQ and metabolic profiles of liver tissue extracts, serum, and urine. A series of proteins and metabolic intermediates were altered during the development of liver injury. These compounds were mainly involved in the metabolism of BAs, FAs and lipids. GPS effectively compensated as shown by shifts in the expression of FXR, ABCB11, ABCB4, CYP7A1, ALDH1L1, and Mrp4, and this effect could prevent hepatic BA accumulation and liver injury. These findings indicated a potential novel and sequential mechanism for the initiation of ANIT-induced liver injury in cholestasis and highlighted several potential therapeutic interventions.
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